Coherus Oncology (NASDAQ: CHRS) CEO receives 375K RSUs and 750K stock options

Rhea-AI Filing Summary

Coherus Oncology President & CEO Dennis M. Lanfear reported new equity awards. On January 23, 2026, he received 375,000 restricted stock units of Coherus Oncology common stock at a price of $0. Each RSU converts into one share, with 50% scheduled to vest on May 20, 2027 and 50% on March 20, 2029, subject to his continued service.

He was also granted a stock option for 750,000 shares of common stock at an exercise price of $2.06 per share, expiring January 23, 2036. The option vests as to one-fourth of the shares on the one-year anniversary of January 23, 2026, and the remainder in equal monthly installments thereafter, contingent on continued service. Following these grants, he holds 1,048,235 shares directly, plus indirect holdings of 432,684 shares through a revocable trust and 86,965 shares through an LLC.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lanfear Dennis M

(Last) (First) (Middle)

C/O COHERUS ONCOLOGY, INC.

333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/23/2026		A		375,000(1)	A	$0	1,048,235	D
Common Stock								432,684	I	By Trust(2)
Common Stock								86,965	I	By LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.06	01/23/2026		A		750,000		(4)	01/23/2036	Common Stock	750,000	$0	750,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest on May 20, 2027 and 50% of the RSUs vest on March 20, 2029, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

2. These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.

3. These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.

4. The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 23, 2026 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

	/s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Coherus Oncology (CHRS) CEO Dennis Lanfear receive?

Dennis M. Lanfear received 375,000 restricted stock units (RSUs) of Coherus Oncology common stock at a price of $0 and a stock option for 750,000 shares with an exercise price of $2.06 per share, both dated January 23, 2026.

How do Dennis Lanfears 375,000 Coherus (CHRS) RSUs vest?

The 375,000 RSUs vest in two tranches: 50% on May 20, 2027 and 50% on March 20, 2029, subject to his continued service relationship with Coherus Oncology on each vesting date.

What are the terms of Dennis Lanfears 750,000 Coherus (CHRS) stock options?

The 750,000 stock options have an exercise price of $2.06 per share and expire on January 23, 2036. One-fourth of the underlying shares vest on the one-year anniversary of January 23, 2026, and the remainder vest in equal monthly installments thereafter, conditioned on continued service.

How many Coherus Oncology (CHRS) shares does Dennis Lanfear own after these transactions?

After the reported awards, Dennis M. Lanfear directly owns 1,048,235 shares of Coherus Oncology common stock. He also has indirect holdings of 432,684 shares through the Lanfear Revocable Trust and 86,965 shares through Lanfear Capital Advisors, LLC.

How are Dennis Lanfears indirect Coherus (CHRS) holdings structured?

Indirect holdings consist of 432,684 shares held by the Lanfear Revocable Trust, where he is a trustee, and 86,965 shares held by Lanfear Capital Advisors, LLC, where he is President.

What is Dennis Lanfears role at Coherus Oncology (CHRS) according to this filing?

The filing identifies Dennis M. Lanfear as a Director and Officer of Coherus Oncology, serving as President & CEO.